These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 2986291)

  • 21. An HTLV-III peptide produced by recombinant DNA is immunoreactive with sera from patients with AIDS.
    Chang NT; Huang J; Ghrayeb J; McKinney S; Chanda PK; Chang TW; Putney S; Sarngadharan MG; Wong-Staal F; Gallo RC
    Nature; 1985 May 9-15; 315(6015):151-4. PubMed ID: 2986016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human T-cell lymphotropic virus type III: immunologic characterization and primary structure analysis of the major internal protein, p24.
    Casey JM; Kim Y; Andersen PR; Watson KF; Fox JL; Devare SG
    J Virol; 1985 Aug; 55(2):417-23. PubMed ID: 2410630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological properties of the Gag protein p24 of the acquired immunodeficiency syndrome retrovirus (human T-cell leukemia virus type III).
    Sarngadharan MG; Bruch L; Popovic M; Gallo RC
    Proc Natl Acad Sci U S A; 1985 May; 82(10):3481-4. PubMed ID: 2582414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients.
    Robey WG; Safai B; Oroszlan S; Arthur LO; Gonda MA; Gallo RC; Fischinger PJ
    Science; 1985 May; 228(4699):593-5. PubMed ID: 2984774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serological differences between human T-lymphotropic virus type-I (HTLV-I) and HTLV-III/LAV.
    Harada S; Purtilo DT; Koyanagi Y; Yamamoto N
    Microbiol Immunol; 1986; 30(6):533-44. PubMed ID: 3018457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III).
    Fischinger PJ; Robey WG; Koprowski H; Gallo RC; Bolognesi DP
    Cancer Res; 1985 Sep; 45(9 Suppl):4694s-4699s. PubMed ID: 2410115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibodies specific for p24, the major core protein of human T-cell leukemia virus type III.
    di Marzo Veronese F; Sarngadharan MG; Rahman R; Markham PD; Popovic M; Bodner AJ; Gallo RC
    Proc Natl Acad Sci U S A; 1985 Aug; 82(15):5199-202. PubMed ID: 2991911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antibodies against human T-cell leukemia virus type III in acquired immunodeficiency syndrome and persistent lymphadenopathy].
    Wernicke D; v d Helm K; Abb J; Eberle J; Zoulek G; Pleyl G; Deinhardt F; Riethmüller G; Ziegler-Heitbrock HW; Rieber EP
    Dtsch Med Wochenschr; 1984 Nov; 109(45):1709-11. PubMed ID: 6094134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence for exposure to HTLV-III in Uganda before 1973.
    Saxinger WC; Levine PH; Dean AG; de Thé G; Lange-Wantzin G; Moghissi J; Laurent F; Hoh M; Sarngadharan MG; Gallo RC
    Science; 1985 Mar; 227(4690):1036-8. PubMed ID: 2983417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I.
    Matsushita S; Robert-Guroff M; Trepel J; Cossman J; Mitsuya H; Broder S
    Proc Natl Acad Sci U S A; 1986 Apr; 83(8):2672-6. PubMed ID: 2422659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene.
    Veronese FD; DeVico AL; Copeland TD; Oroszlan S; Gallo RC; Sarngadharan MG
    Science; 1985 Sep; 229(4720):1402-5. PubMed ID: 2994223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme immunoassay using a novel recombinant polypeptide to detect human immunodeficiency virus env antibody.
    Thorn RM; Beltz GA; Hung CH; Fallis BF; Winkle S; Cheng KL; Marciani DJ
    J Clin Microbiol; 1987 Jul; 25(7):1207-12. PubMed ID: 3475281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determinants of retrovirus (HTLV-III) antibody and immunodeficiency conditions in homosexual men.
    Goedert JJ; Sarngadharan MG; Biggar RJ; Weiss SH; Winn DM; Grossman RJ; Greene MH; Bodner AJ; Mann DL; Strong DM
    Lancet; 1984 Sep; 2(8405):711-6. PubMed ID: 6148471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein.
    Lasky LA; Groopman JE; Fennie CW; Benz PM; Capon DJ; Dowbenko DJ; Nakamura GR; Nunes WM; Renz ME; Berman PW
    Science; 1986 Jul; 233(4760):209-12. PubMed ID: 3014647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HTLV-III: the etiologic agent of AIDS.
    Sarngadharan MG; DeVico AL; Bruch L; Schüpbach J; Gallo RC
    Princess Takamatsu Symp; 1984; 15():301-8. PubMed ID: 6100648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A glycopolypeptide (gp 100) is the main antigen detected by HTLV-III antisera.
    Schneider J; Bayer H; Bienzle U; Hunsmann G
    Med Microbiol Immunol; 1985; 174(1):35-42. PubMed ID: 2987654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus.
    Lange JM; Coutinho RA; Krone WJ; Verdonck LF; Danner SA; van der Noordaa J; Goudsmit J
    Br Med J (Clin Res Ed); 1986 Jan; 292(6515):228-30. PubMed ID: 3004634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sera from patients with multiple sclerosis react with human cell T lymphotropic virus-I gag proteins but not env proteins--Western blotting analysis.
    Ohta M; Ohta K; Mori F; Nishitani H; Saida T
    J Immunol; 1986 Dec; 137(11):3440-3. PubMed ID: 3023483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Viral envelope protein of HTLV-III is the major target antigen for antibodies in hemophiliac patients.
    Kitchen L; Malone G; Orgad S; Barin F; Zaizov R; Ramot B; Gazit E; Kreiss J; Leal M; Wichmann I
    J Infect Dis; 1986 Apr; 153(4):788-90. PubMed ID: 3005438
    [No Abstract]   [Full Text] [Related]  

  • 40. Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.
    Robey WG; Arthur LO; Matthews TJ; Langlois A; Copeland TD; Lerche NW; Oroszlan S; Bolognesi DP; Gilden RV; Fischinger PJ
    Proc Natl Acad Sci U S A; 1986 Sep; 83(18):7023-7. PubMed ID: 3018753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.